Fortrea Holdings (FTRE) Restructuring Costs (2022 - 2023)
Fortrea Holdings (FTRE) posted Restructuring Costs of $7.6 million for Q4 2023, down 34.48% on a QoQ basis from $11.6 million in Q3 2023, and up 181.48% year-over-year from $2.7 million in Q4 2022.
Fortrea Holdings (FTRE) Restructuring Costs (2022 - 2023) Analysis & Trends
Fortrea Holdings' Restructuring Costs history runs 2 years deep, the most recent figure standing at $7.6 million for Q4 2023.
- Quarterly Restructuring Costs rose 181.48% year-over-year to $7.6 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $25.8 million (changed N/A YoY) and the FY2023 annual result came in at $24.3 million, down 20.33% from the prior year.
- Restructuring Costs was $7.6 million for Q4 2023 at Fortrea Holdings, down from $11.6 million in the prior quarter.
- Across five years, Restructuring Costs topped out at $13.0 million in Q2 2022 and bottomed at $2.7 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Fortrea Holdings | 1.83 Bn | 1.68 Bn | 123.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 7.60 Mn |
| Sep 30, 2023 | 11.60 Mn |
| Jun 30, 2023 | 3.90 Mn |
| Dec 31, 2022 | 2.70 Mn |
| Sep 30, 2022 | 5.20 Mn |
| Jun 30, 2022 | 13.00 Mn |